Abstract:Abstract Background One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of the amyloid-β (Aβ) peptide into amyloid plaques. The apolipoprotein E ( APOE ) gene is the strongest genetic risk factor for late-onset AD and has been shown to influence the accumulation of Aβ in the brain in an isoform-dependent manner. ApoE can be produced by different cell types in the brain, with astrocytes being the largest producer of apoE, although reactive microglia also express high levels of apoE. While studies have shown that altering apoE levels in the brain can influence the development of Aβ plaque pathology, it is not fully known how apoE produced by specific cell types, such as astrocytes, contributes to amyloid pathology. Methods We utilized APOE knock-in mice capable of having APOE selectively removed from astrocytes in a tamoxifen-inducible manner and crossed them with the APP/PS1-21 mouse model of amyloidosis. We analyzed the changes to Aβ plaque levels and assessed the impact on cellular responses to Aβ plaques when astrocytic APOE is removed. Results Tamoxifen administration was capable of strongly reducing apoE levels in the brain by markedly reducing astrocyte apoE, while microglial apoE expression remained. Reduction of astrocytic apoE3 and apoE4 led to a large decrease in Aβ plaque deposition and less compact plaques. While overall Iba1 + microglia were unchanged in the cortex after reducing astrocyte apoE, the expression of the disease-associated microglial markers Clec7a and apoE were lower around amyloid plaques, indicating decreased microglial activation. Additionally, astrocyte GFAP levels are unchanged around amyloid plaques, but overall GFAP levels are reduced in the cortex of female apoE4 mice after a reduction in astrocytic apoE. Finally, while the amount of neuritic dystrophy around remaining individual plaques was increased with the removal of astrocytic apoE, the overall amount of cortical amyloid-associated neuritic dystrophy was significantly decreased. Conclusion This study reveals an important role of astrocytic apoE3 and apoE4 on the deposition and accumulation of Aβ plaques as well as on certain Aβ-associated downstream effects.

ApoE facilitates the microglial response to amyloid plaque pathology

Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.

Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis

Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer's disease

Cell-autonomous Effects of APOE4 in Restricting Microglial Response in Brain Homeostasis and Alzheimer’s Disease

APOE4 Impairs Microglia ‐ Astrocyte Crosstalk in Alzheimer Disease

Apolipoprotein D Modulates Amyloid Pathology in APP/PS1 Alzheimer's Disease Mice

APOE4 impairs the microglial response in Alzheimer's disease by inducing TGF-mediated checkpoints

APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints

APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles

Targeting of Nonlipidated, Aggregated Apoe with Antibodies Inhibits Amyloid Accumulation

Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance

Microglial P2X4 receptors promote ApoE degradation and contribute to memory deficits in Alzheimer's disease

ApoE attenuates unresolvable inflammation by complex formation with activated C1q

Apolipoprotein E4 expressed by microglia impairs microglial functions and enhances neurotoxicity

Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease

Apolipoprotein E aggregation in microglia initiates Alzheimer's disease pathology by seeding β-amyloidosis

Peripheral Apoe4 Enhances Alzheimer’s Pathology and Impairs Cognition by Compromising Cerebrovascular Function

A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction with N-terminal Amyloid Precursor Protein, Reduces Β-Amyloid-associated Pathology, and Improves Cognition

Differential Regulation of Amyloid-β Endocytic Trafficking and Lysosomal Degradation by Apolipoprotein E Isoforms

C/EBPβ/AEP Signaling Activated by ApoE4 and 27-Hydroxycholesterol in Macrophages Mediates Cerebral Amyloid Angiopathies in Alzheimer’s Disease